Today: 20 May 2026
Browse Category

NYSE:HUM 3 October 2025 - 4 October 2025

Record Highs, AI Hype, and a Shutdown: Key Takeaways from U.S. Stock Markets (Oct 3–4, 2025)

Record Highs, AI Hype, and a Shutdown: Key Takeaways from U.S. Stock Markets (Oct 3–4, 2025)

The S&P 500 and Dow closed at record highs Friday, with the Dow up 0.5% despite a third day of the U.S. government shutdown. The September jobs report was delayed, but traders expect a Fed rate cut in late October. Utilities and health insurers led gains, while tech stocks lagged. Palantir dropped 7.5% after a U.S. Army memo flagged security issues; Applied Materials fell 3% on China export curbs.
4 October 2025
····
Humana (HUM) Stock Skyrockets on Medicare News – What Investors Must Know Today

Humana Stock Skyrockets as Medicare Advantage News Ignites Rally

Humana shares closed at $283.72 on Oct. 3, 2025, up 10.6% after stronger-than-expected Medicare Advantage metrics and improved 2026 plan benefits. The company reaffirmed 2025 EPS guidance and raised its revenue outlook to at least $128 billion. Humana will reduce its Medicare Advantage footprint to 85% of U.S. counties next year. Trading volume spiked as investors reacted to the news.
3 October 2025
·
Humana (HUM) Stock Skyrockets on Medicare News – What Investors Must Know Today

Humana (HUM) Stock Skyrockets on Medicare News – What Investors Must Know Today

Humana shares jumped over 6% to $272.05 midday Oct 3 after the company reported a sharp rise in Medicare Advantage star ratings for 2026. The stock rebounded from last week’s drop, which followed news of Humana cutting its Medicare Advantage footprint. Wall Street consensus remains neutral, with a $289 average price target. Year-to-date, shares are flat and about 19% below their 52-week high.
3 October 2025
·
1 2 3

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Go toTop